APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phosphodiesterase-4 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Phosphodiesterase-4 Inhibitor Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchPhosphodiesterase-4 Inhibitor Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphodiesterase-4 Inhibitor Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Phosphodiesterase-4 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphodiesterase-4 Inhibitor Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphodiesterase-4 Inhibitor Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Phosphodiesterase-4 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Phosphodiesterase-4 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phosphodiesterase-4 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phosphodiesterase-4 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Phosphodiesterase-4 Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Phosphodiesterase-4 Inhibitor market include GSK, Fosun-Pharmaceutical, Amgen, AstraZeneca, Camber Pharmaceuticals and Arcutis Biotherapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Phosphodiesterase-4 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phosphodiesterase-4 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phosphodiesterase-4 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Phosphodiesterase-4 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Phosphodiesterase-4 Inhibitor Segment by Company

GSK

Fosun-Pharmaceutical

Amgen

AstraZeneca

Camber Pharmaceuticals

Arcutis Biotherapeutics

Phosphodiesterase-4 Inhibitor Segment by Type

Oral

External Use

Phosphodiesterase-4 Inhibitor Segment by Application

Children

Adults

Phosphodiesterase-4 Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Phosphodiesterase-4 Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Phosphodiesterase-4 Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phosphodiesterase-4 Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Phosphodiesterase-4 Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphodiesterase-4 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphodiesterase-4 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphodiesterase-4 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Phosphodiesterase-4 Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phosphodiesterase-4 Inhibitor industry.

Chapter 3: Detailed analysis of Phosphodiesterase-4 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Phosphodiesterase-4 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Phosphodiesterase-4 Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phosphodiesterase-4 Inhibitor Industry Trends Table 2. Phosphodiesterase-4 Inhibitor Industry Drivers Table 3. Phosphodiesterase-4 Inhibitor Industry Opportunities and Challenges Table 4. Phosphodiesterase-4 Inhibitor Industry Restraints Table 5. Global Phosphodiesterase-4 Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phosphodiesterase-4 Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Phosphodiesterase-4 Inhibitor Sales Volume by Company (k units) & (2021-2026) Table 8. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Phosphodiesterase-4 Inhibitor Average Price (US$/unit) of Company (2021-2026) Table 10. Global Phosphodiesterase-4 Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Phosphodiesterase-4 Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Phosphodiesterase-4 Inhibitor Company, Product Type & Application Table 13. Global Phosphodiesterase-4 Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Phosphodiesterase-4 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of External Use Table 19. Global Phosphodiesterase-4 Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Phosphodiesterase-4 Inhibitor Sales Volume by Type (2021-2026) & (k units) Table 21. Global Phosphodiesterase-4 Inhibitor Sales Volume by Type (2027-2032) & (k units) Table 22. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Type (2021-2026) Table 23. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Type (2027-2032) Table 24. Global Phosphodiesterase-4 Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Phosphodiesterase-4 Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Phosphodiesterase-4 Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Type (2021-2026) Table 28. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Children Table 30. Significant Companies of Adults Table 31. Global Phosphodiesterase-4 Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Phosphodiesterase-4 Inhibitor Sales Volume by Application (2021-2026) & (k units) Table 33. Global Phosphodiesterase-4 Inhibitor Sales Volume by Application (2027-2032) & (k units) Table 34. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Application (2021-2026) Table 35. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Application (2027-2032) Table 36. Global Phosphodiesterase-4 Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Phosphodiesterase-4 Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Phosphodiesterase-4 Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Application (2021-2026) Table 40. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Application (2027-2032) Table 41. Global Phosphodiesterase-4 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Phosphodiesterase-4 Inhibitor Sales by Region (2021-2026) & (k units) Table 43. Global Phosphodiesterase-4 Inhibitor Sales Market Share by Region (2021-2026) Table 44. Global Phosphodiesterase-4 Inhibitor Sales by Region (2027-2032) & (k units) Table 45. Global Phosphodiesterase-4 Inhibitor Sales Market Share by Region (2027-2032) Table 46. Global Phosphodiesterase-4 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Phosphodiesterase-4 Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Region (2021-2026) Table 49. Global Phosphodiesterase-4 Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Region (2027-2032) Table 51. Global Phosphodiesterase-4 Inhibitor Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Phosphodiesterase-4 Inhibitor Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Phosphodiesterase-4 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Phosphodiesterase-4 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Phosphodiesterase-4 Inhibitor Sales by Country (2021-2026) & (k units) Table 56. Global Phosphodiesterase-4 Inhibitor Sales Market Share by Country (2021-2026) Table 57. Global Phosphodiesterase-4 Inhibitor Sales by Country (2027-2032) & (k units) Table 58. Global Phosphodiesterase-4 Inhibitor Sales Market Share by Country (2027-2032) Table 59. Global Phosphodiesterase-4 Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Phosphodiesterase-4 Inhibitor Sales Value Market Share by Country (2021-2026) Table 61. Global Phosphodiesterase-4 Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Phosphodiesterase-4 Inhibitor Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. GSK Phosphodiesterase-4 Inhibitor Product Portfolio Table 67. GSK Recent Development Table 68. Fosun-Pharmaceutical Company Information Table 69. Fosun-Pharmaceutical Business Overview Table 70. Fosun-Pharmaceutical Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Fosun-Pharmaceutical Phosphodiesterase-4 Inhibitor Product Portfolio Table 72. Fosun-Pharmaceutical Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Amgen Phosphodiesterase-4 Inhibitor Product Portfolio Table 77. Amgen Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. AstraZeneca Phosphodiesterase-4 Inhibitor Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Camber Pharmaceuticals Company Information Table 84. Camber Pharmaceuticals Business Overview Table 85. Camber Pharmaceuticals Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Camber Pharmaceuticals Phosphodiesterase-4 Inhibitor Product Portfolio Table 87. Camber Pharmaceuticals Recent Development Table 88. Arcutis Biotherapeutics Company Information Table 89. Arcutis Biotherapeutics Business Overview Table 90. Arcutis Biotherapeutics Phosphodiesterase-4 Inhibitor Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Arcutis Biotherapeutics Phosphodiesterase-4 Inhibitor Product Portfolio Table 92. Arcutis Biotherapeutics Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Phosphodiesterase-4 Inhibitor Distributors List Table 96. Phosphodiesterase-4 Inhibitor Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Phosphodiesterase-4 Inhibitor Product Image Figure 2. Global Phosphodiesterase-4 Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Phosphodiesterase-4 Inhibitor Sales (2021-2032) & (k units) Figure 5. Global Phosphodiesterase-4 Inhibitor Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Phosphodiesterase-4 Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. External Use Image Figure 11. Global Phosphodiesterase-4 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Phosphodiesterase-4 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Type (2021-2032) Figure 14. Global Phosphodiesterase-4 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Phosphodiesterase-4 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Type (2021-2032) Figure 17. Children Image Figure 18. Adults Image Figure 19. Global Phosphodiesterase-4 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Phosphodiesterase-4 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Application (2021-2032) Figure 22. Global Phosphodiesterase-4 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Phosphodiesterase-4 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Application (2021-2032) Figure 25. Global Phosphodiesterase-4 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Phosphodiesterase-4 Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Phosphodiesterase-4 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Phosphodiesterase-4 Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 30. North America Phosphodiesterase-4 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Phosphodiesterase-4 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Phosphodiesterase-4 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. South America Phosphodiesterase-4 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Phosphodiesterase-4 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Phosphodiesterase-4 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Phosphodiesterase-4 Inhibitor Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Phosphodiesterase-4 Inhibitor Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • External Use
Applications
  • Children
  • Adults
Companies covered
  • GSK
  • Fosun-Pharmaceutical
  • Amgen
  • AstraZeneca
  • Camber Pharmaceuticals
  • Arcutis Biotherapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Phosphodiesterase-4 Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Phosphodiesterase-4 Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Phosphodiesterase-4 Inhibitor Market Dynamics
  1. 2.1 Phosphodiesterase-4 Inhibitor Industry Trends
  2. 2.2 Phosphodiesterase-4 Inhibitor Industry Drivers
  3. 2.3 Phosphodiesterase-4 Inhibitor Industry Opportunities and Challenges
  4. 2.4 Phosphodiesterase-4 Inhibitor Industry Restraints
3 Phosphodiesterase-4 Inhibitor Market by Company
  1. 3.1 Global Phosphodiesterase-4 Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Phosphodiesterase-4 Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Phosphodiesterase-4 Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Phosphodiesterase-4 Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Phosphodiesterase-4 Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Phosphodiesterase-4 Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Phosphodiesterase-4 Inhibitor Company Product Type and Application
  8. 3.8 Global Phosphodiesterase-4 Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Phosphodiesterase-4 Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Phosphodiesterase-4 Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Phosphodiesterase-4 Inhibitor Market by Type
  1. 4.1 Phosphodiesterase-4 Inhibitor Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 External Use
  4. 4.2 Global Phosphodiesterase-4 Inhibitor Sales Volume by Type
  5. 4.2.1 Global Phosphodiesterase-4 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Phosphodiesterase-4 Inhibitor Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Phosphodiesterase-4 Inhibitor Sales Value by Type
  9. 4.3.1 Global Phosphodiesterase-4 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Phosphodiesterase-4 Inhibitor Sales Value by Type (2021-2032)
  11. 4.3.3 Global Phosphodiesterase-4 Inhibitor Sales Value Share by Type (2021-2032)
5 Phosphodiesterase-4 Inhibitor Market by Application
  1. 5.1 Phosphodiesterase-4 Inhibitor Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adults
  4. 5.2 Global Phosphodiesterase-4 Inhibitor Sales Volume by Application
  5. 5.2.1 Global Phosphodiesterase-4 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Phosphodiesterase-4 Inhibitor Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Phosphodiesterase-4 Inhibitor Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Phosphodiesterase-4 Inhibitor Sales Value by Application
  9. 5.3.1 Global Phosphodiesterase-4 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Phosphodiesterase-4 Inhibitor Sales Value by Application (2021-2032)
  11. 5.3.3 Global Phosphodiesterase-4 Inhibitor Sales Value Share by Application (2021-2032)
6 Phosphodiesterase-4 Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Phosphodiesterase-4 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phosphodiesterase-4 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Phosphodiesterase-4 Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Phosphodiesterase-4 Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Phosphodiesterase-4 Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Phosphodiesterase-4 Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Phosphodiesterase-4 Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Phosphodiesterase-4 Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Phosphodiesterase-4 Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Phosphodiesterase-4 Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Phosphodiesterase-4 Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Phosphodiesterase-4 Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Phosphodiesterase-4 Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Phosphodiesterase-4 Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Phosphodiesterase-4 Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Phosphodiesterase-4 Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Phosphodiesterase-4 Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phosphodiesterase-4 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Phosphodiesterase-4 Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Phosphodiesterase-4 Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Phosphodiesterase-4 Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Phosphodiesterase-4 Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Phosphodiesterase-4 Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Phosphodiesterase-4 Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Phosphodiesterase-4 Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Phosphodiesterase-4 Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Phosphodiesterase-4 Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Phosphodiesterase-4 Inhibitor Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Fosun-Pharmaceutical
  8. 8.2.1 Fosun-Pharmaceutical Company Information
  9. 8.2.2 Fosun-Pharmaceutical Business Overview
  10. 8.2.3 Fosun-Pharmaceutical Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Fosun-Pharmaceutical Phosphodiesterase-4 Inhibitor Product Portfolio
  12. 8.2.5 Fosun-Pharmaceutical Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Phosphodiesterase-4 Inhibitor Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Phosphodiesterase-4 Inhibitor Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Camber Pharmaceuticals
  26. 8.5.1 Camber Pharmaceuticals Company Information
  27. 8.5.2 Camber Pharmaceuticals Business Overview
  28. 8.5.3 Camber Pharmaceuticals Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Camber Pharmaceuticals Phosphodiesterase-4 Inhibitor Product Portfolio
  30. 8.5.5 Camber Pharmaceuticals Recent Developments
  31. 8.6 Arcutis Biotherapeutics
  32. 8.6.1 Arcutis Biotherapeutics Company Information
  33. 8.6.2 Arcutis Biotherapeutics Business Overview
  34. 8.6.3 Arcutis Biotherapeutics Phosphodiesterase-4 Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Arcutis Biotherapeutics Phosphodiesterase-4 Inhibitor Product Portfolio
  36. 8.6.5 Arcutis Biotherapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Phosphodiesterase-4 Inhibitor Value Chain Analysis
  2. 9.1.1 Phosphodiesterase-4 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Phosphodiesterase-4 Inhibitor Sales Mode & Process
  6. 9.2 Phosphodiesterase-4 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Phosphodiesterase-4 Inhibitor Distributors
  9. 9.2.3 Phosphodiesterase-4 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst